Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
110actual
Sites
26
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-24 | actual | When the study began enrolling |
| Primary completion | 2024-01-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-05 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-29 | actual | When this record first appeared on the registry |
| Results posted | 2025-06-29 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-resistant Prostate Cancer
Interventions
- Drug: olaparib — also filed as Lynparza
- Drug: abiraterone acetate — also filed as Zytiga
Primary outcome
what the primary-completion date above is the date OFRadiological Progression Free Survival (rPFS)
measured Tumour imaging CT/MRI and bone scan were assessed every 8 weeks from randomisation to week 24 and then every 12 weeks until RECIST progression. Patients were followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-01-30 · 4.5 MB · Prot_008.pdf
Statistical Analysis Planposted 2021-05-21 · 318 KB · SAP_009.pdf
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed